Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107297 | 0.89 | MAPK14 (0.43) | MAPK14TRPA1MAPK11PIM1PIM2 | |
| SCHEMBL4017606 | 0.85 | MAPK14 (0.48) | MAPK14TRPA1MAP4K4PIM1PIM2 | |
| SCHEMBL4017462 | 0.76 | MAPK14 (0.40) | MAPK14TRPA1MAPK11MAP4K4 | |
| SCHEMBL14814238 | 0.76 | MAP4K4 (0.53) | MAPK14TRPA1MAPK11MAP4K4 | |
| SCHEMBL3972688 | 0.74 | MAPK14 (0.43) | MAPK14MAPK11 | |
| SCHEMBL5100000 | 0.73 | MAPK14 (0.61) | MAPK14TRPA1MAPK11PIM1 | |
| SCHEMBL14018970 | 0.73 | MAPK14 (0.44) | MAPK14TRPA1MAPK11PDE10A | |
| SCHEMBL4013145 | 0.73 | MAPK14 (0.46) | MAPK14MAPK11 | |
| SCHEMBL13764813 | 0.73 | MAPK14 (0.46) | MAPK14MAPK11 | |
| SCHEMBL4836915 | 0.73 | MAPK14 (0.44) | MAPK14TRPA1MAPK11PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | MAP3K1, MAP3K21, MAP3K2 | MAPK14 48/4885TRPA1 4334/4885MAPK11 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.